Ampliphi Biosciences Corp., of San Diego, said the FDA provided positive feedback on the company's previously submitted detailed development proposal to start a phase II trial with its bacteriophage cocktail AB-SA01 for the treatment of antibiotic-resistant Staphylococcus aureus infections in patients with chronic rhinosinusitis.